
欧洲医疗第二意见市场预测至 2027 年 - COVID-19 影响和按疾病(癌症、骨科疾病、心脏疾病、神经系统疾病、肾病、血液系统疾病、慢性阻塞性肺病、器官移植和其他疾病)和服务提供商进行的区域分析(医院、健康保险公司和在线服务)
No. of Pages: 115 | Report Code: TIPRE00025236 | Category: Life Sciences
No. of Pages: 115 | Report Code: TIPRE00025236 | Category: Life Sciences
医疗第二意见旨在提供有关患者当前治疗选择的有价值的信息。这一概念在处理因针对单个病例推荐各种治疗方案而造成的混乱方面发挥着重要作用。此外,还寻求该意见以获得更多信息,这有助于改善疾病的治疗结果。医学第二意见可以验证诊断;因此,它在提高治疗准确性方面发挥着重要作用。
欧洲医疗第二意见市场预计将从2020年的11.1644亿美元增至2027年的32.5299亿美元;预计 2020 年至 2027 年复合年增长率为 16.5%。市场的增长归因于人们越来越重视卓越的治疗结果以及越来越倾向于医疗保健成本优化。然而,全球范围内缺乏使用医疗第二意见的明确指南可能会对预测期内的市场增长产生负面影响。
远程医疗技术结合了现代通信平台,旨在进行患者和医疗保健专业人员之间的虚拟互动。远程医疗技术的采用使得医生和患者能够跨越地理界限进行交流。远程医疗技术的显着优势和不断增长的投资可能会在预测期内为医疗第二意见市场提供利润丰厚的增长机会。例如,2020 年 3 月,New Capital Partners 投资了 TeleHealth Solution (THS),以开发新的远程医疗技术。这些新技术对于护理服务、长期护理和辅助生活设施将非常有用。借助这笔投资,该公司计划推出预咨询、第二医疗意见和预约平台,为大量人群提供便捷的医疗服务。预计到 2027 年,对远程医疗技术的投资数量不断增加,将为市场增长提供利润丰厚的机会。此外,软件开发公司和医疗机构之间不断增加的伙伴关系和协作正在加速医疗咨询服务的数字化。医疗第二意见服务日益数字化预计将为市场增长提供利润丰厚的机会。
欧洲国家受到了 COVID-19 大流行的严重影响。患者人数增加;由于案件的复杂性或在所有案件中缺乏深厚的专业知识和实践,可能会发生错误。然而,假阴性的存在使得诊断变得困难,尤其是在疾病的早期阶段。因此,获得第二意见可能是一个重要的步骤,特别是在 COVID-19 的诊断和治疗计划存在任何不确定性的情况下。因此,欧洲对医疗第二意见的需求不断增长可能会对预测期内的市场增长产生积极影响。
根据疾病,欧洲医疗第二意见市场分为癌症、糖尿病、心脏病、神经系统疾病、肾脏疾病、血液疾病、慢性阻塞性肺病、骨科疾病、器官移植和其他疾病。癌症细分市场在 2019 年占据最大市场份额。然而,预计骨科疾病细分市场在预测期内的复合年增长率最高。
基于服务提供商,欧洲医疗第二意见市场分为医院、健康保险公司和在线服务。 2019年,医院细分市场占据最大市场份额;然而,在线服务领域预计在预测期内的市场复合年增长率最高。
p>
与本报告相关的主要和次要来源欧洲医疗第二意见市场包括欧洲制药工业协会联合会(EFPIA)、欧洲医学协会(EMA)和经济合作与发展组织(OECD)。
Strategic insights for Europe Medical Second Opinion involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2020 | US$ 1,116.44 Million |
Market Size by 2027 | US$ 3,252.99 Million |
Global CAGR (2020 - 2027) | 16.5% |
Historical Data | 2018-2019 |
Forecast period | 2021-2027 |
Segments Covered |
By 疾病
|
Regions and Countries Covered | 欧洲
|
Market leaders and key company profiles |
The regional scope of Europe Medical Second Opinion refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Medical Second Opinion Market is valued at US$ 1,116.44 Million in 2020, it is projected to reach US$ 3,252.99 Million by 2027.
As per our report Europe Medical Second Opinion Market, the market size is valued at US$ 1,116.44 Million in 2020, projecting it to reach US$ 3,252.99 Million by 2027. This translates to a CAGR of approximately 16.5% during the forecast period.
The Europe Medical Second Opinion Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Medical Second Opinion Market report:
The Europe Medical Second Opinion Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Medical Second Opinion Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Medical Second Opinion Market value chain can benefit from the information contained in a comprehensive market report.